Matching placebo tablets without active substance

DRUG3 trials

Sponsors

Biogen Idec Research Limited, Daiichi Sankyo Inc., Boehringer Ingelheim International GmbH

Conditions

Acute myeloid leukemiaCrohn`s Disease (CD)Parkinson's Disease

Phase 2

283PD201 (LUMA): A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants with Parkinson’s Disease

Active, not recruitingCTIS2023-505645-12-00

Biogen Idec Research LimitedParkinson's Disease

Start: 2022-11-28Target: 311Updated: 2026-01-09

A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with Crohn`s Disease (CD) receiving ustekinumab induction treatment

CompletedCTIS2024-512756-38-00

Boehringer Ingelheim International GmbHCrohn`s Disease (CD)

Start: 2022-02-17End: 2024-08-08Target: 27Updated: 2024-08-05

Phase 3

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia (QuANTUM-Wild)

RecruitingCTIS2023-507936-20-00

Daiichi Sankyo Inc.Acute myeloid leukemia

Start: 2025-05-05Target: 267Updated: 2025-12-16

Related Papers

QuANTUM-Wild: A phase 3, randomized, double-blind, placebo-controlled trial of quizartinib in combination with chemotherapy and as single-agent maintenance in <i>FLT3</i> -ITD–negative acute myeloid leukemia (AML).

Journal of Clinical Oncology2025-05-28

Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, <i>FLT3</i>-ITD-Negative Acute Myeloid Leukemia

Blood2024-11-054 citations